Harnessing Long Residence Time to Overcome Hormone Fluctuations in Advancing MC2R Antagonists Toward the Clinic
- Optimizing a long-residence MC2R antagonist that maintains efficacy despite large hormone surges, benefiting patients where fast-off antagonists lose effect
- Building an HPA-axis systems biology and PBPK framework allowing confident prediction of human responses before first-in-human studies
- Recreating human-challenge paradigms in aligned in vivo models demonstrating clear advantages of long-residence compounds and benefiting clinical translation